Literature DB >> 10438702

Genes encoding tumor-specific antigens are expressed in human myeloma cells.

N van Baren1, F Brasseur, D Godelaine, G Hames, A Ferrant, F Lehmann, M André, C Ravoet, C Doyen, G C Spagnoli, M Bakkus, K Thielemans, T Boon.   

Abstract

Genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1 families encode antigenic peptides that are presented by HLA class I molecules and that are recognized on human tumors by autologous cytolytic T lymphocytes. These genes are expressed in many solid tumor types but not in normal tissues, except male germline cells. Because the latter cells are devoid of HLA molecules, the derived antigens are strictly tumor-specific and should constitute safe immunogens for cancer immunotherapy. We detected a significant expression of these genes in a high proportion of bone marrow samples from patients with advanced multiple myeloma. This observation provides a basis for clinical trials aimed at inducing a cellular immune response directed at malignant plasma cells in advanced myeloma patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438702

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Authors:  Andrew McLarnon; Karen P Piper; Oliver C Goodyear; Julie M Arrazi; Premini Mahendra; Mark Cook; Fiona Clark; Guy Pratt; Charles Craddock; Paul A H Moss
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

2.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

3.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 4.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

5.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

Authors:  Frits van Rhee; Susann M Szmania; Fenghuang Zhan; Sushil K Gupta; Mindy Pomtree; Pei Lin; Ramesh B Batchu; Amberly Moreno; Guilio Spagnoli; John Shaughnessy; Guido Tricot
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

6.  MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Authors:  Caroline Poli; Caroline Raffin; Danijel Dojcinovic; Immanuel Luescher; Maha Ayyoub; Danila Valmori
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

7.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 8.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

10.  Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells.

Authors:  Charles De Smet; Axelle Loriot; Thierry Boon
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.